Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Arbutus Biopharma Corporation (ABUS) had Consolidated Net Income/Loss of $169.69M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$179.13M |
|
$169.69M |
|
-- |
|
$179.13M |
|
$10.22M |
|
$168.91M |
|
$0.79M |
|
$169.69M |
|
$169.69M |
|
$169.69M |
|
$169.69M |
|
|
Consolidated Net Income/Loss |
$169.69M |
$169.69M |
|
$168.91M |
|
$168.92M |
|
193.77M |
|
195.21M |
|
$0.88 |
|
$0.87 |
|
| Balance Sheet Financials | |
$277.01M |
|
$0.02M |
|
$0.15M |
|
$277.16M |
|
$5.11M |
|
-- |
|
$11.88M |
|
$16.99M |
|
$260.18M |
|
$260.18M |
|
$260.18M |
|
196.95M |
|
| Cash Flow Statement Financials | |
$-8.11M |
|
$2.20M |
|
$11.62M |
|
$18.01M |
|
$23.71M |
|
$5.70M |
|
$1.36M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
54.26 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
94.30% |
|
94.30% |
|
-- |
|
94.73% |
|
94.73% |
|
$-8.11M |
|
-- |
|
-- |
|
-- |
|
0.65 |
|
-- |
|
0.99 |
|
90.47 |
|
65.22% |
|
65.22% |
|
61.23% |
|
65.22% |
|
$1.32 |
|
$-0.04 |
|
$-0.04 |
|